Incretin-based therapies for type 2 diabetes with nonalcoholic fatty liver disease: a systematic review and meta-analysis

doi:10.5246/jcps.2016.03.025

Abstract

Abstract:

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the effectiveness and safety of incretin-based therapies (IBTs) for the treatment of type 2 diabetes (T2DM) with nonalcoholic fatty liver disease (NAFLD). Electronic databases such as the Cochrane library, EMbase, PubMed, and three Chinese databases were searched for RCTs that compared IBTs with other treatments or placebo for T2DM with NAFLD. Two reviewers independently assessed the risk of bias, extracted, and analyzed the data. A meta-analysis was performed using Revman 5.2. Publication bias was evaluated. Seven RCTs involving 532 patients were ultimately included. The results of meta-analysis (random-effects model)revealed that IBTs had a significant reduction in serum ALT (WMD –12.30, 95% CI –17.53~–7.06) and BMI (WMD –2.64, 95% CI –4.35~–0.94). However, there was no significant difference in other outcomes including HbA1c, AST, TC, TG and HOMA-RA. IBTs were well tolerated by patients but the evidence was limited. The significant decrease in hepatic biochemical markers following treatment with IBTs, as well as improvements in BMI, suggested that IBTs may be an effective option for T2DM with NAFLD.

Key words: Incretin-based therapies, Dipeptidyl peptidase-4 inhibitor, Glucagon-like peptide-1 receptor agonist, Type 2 diabetes, Nonalcoholic fatty liver disease, Meta-analysis, Randomized controlled trial

CLC Number:

R977

Supporting:

Qin Hu, Hulin Tang, Hong Shao. Incretin-based therapies for type 2 diabetes with nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(3): 206-214.

References

[1] Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Diabetes Res. Clin. Pract. 2010, 87, 4-14.

[2] Blaslov, K.; Zibar, K.; Bulum, T.; Duvnjak, L. Clin. Res. Hepatol. Gastroenterol. 2014, 38, 61-63.

[3] Fan, J.G.; Saibara, T.; Chitturi, S.; Kim, B.I.; Sung, J.J. J. Gastroenterol. Hepatol. 2007, 22, 794-800.

[4] de Alwis, N.M.; Day, C.P. J. Hepatol. 2008, 48, 104-112.

[5] Farrell, G.C.; Larter, C.Z. Hepatology. 2006, 43, 99-112.

[6] Ali, R.; Cusi, K. Ann. Med. 2009, 41, 265-278.

[7] Charbonnel, B.; Bertolini, M.; Tinahones, F.J.; Domingo, M.P.; Davies, M. J. Diabetes. Complications. 2014, 28, 880-886.

[8] Olaywi, M.; Bhatia, T.; Anand, S.; Singhal, S. Hepatobiliary Pancreat. Dis. Int. 2013, 12, 584-588.

[9] Carbone, L.J.; Angus, P.W.; Yeomans, N.D. J. Gastroenterol. Hepatol. 2015, 327-329.

[10] Ohki, T.; Isogawa, A.; Iwamoto, M.; Ohsuqi, M.; Yoshida, H. Sci. World J. 2012, 496-453.

[11] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease. Chin. J. Hepat. 2006, 14, 161-163.

[12] Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M. Gastroenterology. 2012, 142, 1592-1609.

[13] Loria, P.; Adinolfi, L.E.; Bellentani, S.; Bugianesi, E.; Grieco, A. Dig. Liver Dis. 2010, 42, 272-282.

[14] Fan, J.G.; Cai, X.B. Drug Evaluation. 2007, 4, 80-81.

[15] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease. Chin. J. Hepatol. (electronic edition). 2010, 2, 43-48.

[16] Cuthbertson, D.J.; Irwin, A.; Gardner, C.J.; Daousi, C.; Purewal, T. PLoS One. 2012, 7, e50117.

[17] Higgins JPT GSE Cochrane Handbook for Systematic Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available: www.cochranehand-book.org. 2011.

[18] Fan, H.; Pan, Q.; Xu, Y.; Yang, X. Arq. Bras. Endocrinol. Metabol. 2014, 57, 702-708.

[19] Shao, N.; Kuang, H.Y.; Hao, M.; Gao, X.Y.; Lin, W.J. Diabetes Metab. Res. Rev. 2014, 30, 521-529.

[20] Song, X.X.; Jiang, T.; Kang, K.; Wen, Z. Chin. J. New Drug. 2014, 23, 215-218.

[21] Bao, M.J.; Wu, J.C.; Yang, Y.; Zhang, L.; Zhu, X.J. Pract. J. Clin. Med. 2014, 11, 70-72.

[22] Jin, H.L.; Zhao, H.Y.; Li, Y.H.; Jia, S.E.; Ma, L.N. Harbin Med. J. 2014, 34, 279-281.

[23] Liang, L.F.; Xu, M.; Zhang, H.L.; Yang, H.; Zhang, E.S. J. Front. Med. 2014, 220-221.

[24] Wang, Y.; Dai, Y. China Pharma. 2014, 23, 107-108.

[25] Armstrong, M.J.; Houlihan, D.D.; Rowe, I.A.; Clausen, W.H.; Elbrønd, B. Aliment. Pharmacol. Ther. 2013, 37, 234-242.

[26] Gluud, L.L.; Knop, F.K.; Vilsboll, T. Bmj. Open. 2014, 4, e005325.

[27] Blaslov, K.; Zibar, K.; Bulum, T.; Duvnjak, L. Clin. Res. Hepatol. Gastroenterol. 2014, 38, e61-63.

[28] Petersen, K.F.; Dufour, S.; Befroy, D.; Lehrke, M.; Hendler, R.E. Diabetes. 2005, 54, 603-608.

[29] Belfort, R.; Harrison, S.A.; Brown, K.; Darland, C.; Finch, J. N. Engl. J. Med. 2006, 355, 2297-2307.

[30] Karlas, T.; Wiegand, J.; Berg, T. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 195-208.

[31] Xie, X.H.; Wang, F.; Cui, J.Y. J. Chin. Pharm. Sci. 2015, 24, 412-418.

[32] Eguchi, Y.; Kitajima, Y.; Hyogo, H.; Takahashi, H.; Kojima, M. Hepatol. Res. 2015, 45, 269-278.

[33] Zhang, L.X.; Wei, C.; Wei, X.D.; Liu, Y.; Chen, D.H. Chin. J. Modern Drug Appl. 2015, 9, 120-122.